On July 1st, the Medical Administration Bureau of the National Health Commission issued the “Notification on printing the first List of National Intensive Monitoring Drug (Chemicals and Biological Products),” 20 drugs were selected in the “List.” The “Notification” stipulates that all provinces should form a list of provincial intensive monitoring drug on the basis of the national “List” and publish it for use by various medical institutions. All medical institutions should establish a regulatory system for monitoring drugs and strengthen the management of clinical applications of them. At the same time, the prescription management of drugs outside the “List” should also be strengthened.
重磅！国家重点监控药品目录公布
来源：医药网 2019.07.02
核心提示：7月1日，国家卫健委医政医管局发布了《关于印发第一批国家重点监控合理用药药品目录（化药及生物制品）的通知》，共20个药品入选。 《通知》要求， 各省应在《目录》基础上形成省级重点监控合理用药药品目录并公布，以供各类医疗机构参考；各医疗机构要建立重点监控合理用药药品管理制度，加强目录内药品临床应用的全程管理；同时，还应加强目录外药品的处方管理。
Leave a Reply